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Edited by Ulrike KutayAbstract Xenopus laevis RNA-binding protein A (Xlrbpa) is a
highly conserved, ubiquitously expressed hnRNP- and ribosome-
associated RNA-binding protein that contains three double
stranded RNA-binding domains (dsRBDs) in tandem arrange-
ment. A two-hybrid screen with Xlrbpa as a bait recovered
Xlrbpa itself as the strongest interaction partner, indicating
multimerization of this protein. To search for regions responsible
for the observed interaction, we conducted two-hybrid assays
with Xlrbpa deletion constructs and identiﬁed the third dsRBD of
Xlrbpa as the exclusive interacting domain. Additionally, these
results were conﬁrmed by coimmunoprecipitation experiments
with truncated proteins expressed both in yeast and Xenopus
oocytes. In PACT, the human homologue of Xlrbpa, we could
demonstrate that the third dsRBD displays the same multimer-
ization activity. Interestingly, this domain is essential for the
activation of the dsRNA-activated protein kinase PKR. Addition
of RNAses to coimmunoprecipitation experiments did not aﬀect
the dimerization, suggesting that the interaction is independent
of RNA-binding. We report here a homomultimerization activity
of a type B dsRBD and suggest possible implications that include
a model for PKR activation by PACT.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The double-stranded RNA-binding domain (dsRBD) is
found in more than 100 proteins from diﬀerent organisms
ranging from Escherichia coli to humans. dsRBDs are ap-
proximately 70 amino acids in length and can bind double-
stranded RNA (dsRNA) but neither single-stranded RNA
(ssRNA) nor DNA [1,2]. By sequence comparison, dsRBDs
can be divided into two types: type-A dsRBDs are conserved
over the entire length of a deﬁned consensus sequence, whereas
type-B dsRBDs ﬁt the consensus only at the C-terminal end
[1]. In vitro RNA-binding experiments demonstrated that only
type-A dsRBDs are competent in dsRNA binding, while type-
B domains fail to bind RNA by themselves. However, the
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crystal structures of several type-A dsRBDs have been solved
[5–8] all showing a general abbba structure of the domain in
which the two a-helices lie on one side of a three stranded anti-
parallel b-sheet. Furthermore, the NMR structure of the sec-
ond dsRBD of PKR, which is of type-B, shows the same
general architecture suggesting that at least some type-B do-
mains show the same structure as type-A domains [7].
Xlrbpa is a 33 kDa, ubiquitously expressed, double-stran-
ded RNA-binding protein that is associated with the majority
of cellular RNAs, ribosomal RNAs and hnRNAs [9]. Xlrbpa
is composed of three dsRBDs in tandem arrangement, the
ﬁrst two are of type-A whereas the third is type-B. The sec-
ond but neither the ﬁrst nor the third dsRBD of Xlrbpa is
able to bind dsRNA as an isolated domain in vitro. Xlrbpa is
highly homologous to human PACT and mouse RAX pro-
teins, respectively. Both of these mammalian proteins were
shown to be cellular activators of the interferon induced,
dsRNA-activated protein kinase PKR [10,11]. Additional
work on PACT and PKR indicated that the ﬁrst and second
domains of PACT are responsible for a physical interaction
with PKR, whereas the third domain of PACT is responsible
for activation.
Several proteins can be coimmunoprecipitated with Xlrbpa,
including hnRNPs and ribosomal components [9]. Therefore,
to search for interacting partners, we performed a yeast two-
hybrid screen of an embryonic Xenopus laevis cDNA library
using Xlrbpa as a bait. Amongst the positives recovered from
the screen, Xlrbpa itself turned out to be the strongest inter-
action partner. To determine the minimal region of Xlrbpa
required for multimerization we performed two-hybrid assays
and coimmunoprecipitation experiments of tagged Xlrbpa
deletion constructs. These experiments identiﬁed the highly
conserved third, type-B dsRBDs of Xlrbpa and PACT as the
sole regions within these homologues that show multimeriza-
tion activity.2. Materials and methods
2.1. Two-hybrid-screen, expression vectors and antibodies
The two-hybrid screen with Xlrbpa as bait was performed according
to the user manual of MATCHMAKER LexA two-hybrid system
from Clontech (Palo Alto, CA) using Saccharomyces cerevisiae strain
EGY48C (MATa, his2, trp1, ura3, LexAop(x6)-LEU2) that was co-
transformed with the bait vectors pLexA expressing Xlrbpa and the
prey vector pB42AD that expressed the Xenopus cDNA library. The
EGY48C strains carried plasmid p8op-lacZ containing the LacZ re-
porter gene under control of the LexA operator. To measure the
strength of the two-hybrid interaction, b-galactosidase liquid culture
assays using o-nitrophenyl-b-D-galactopyranoside (ONPG) asblished by Elsevier B.V. All rights reserved.
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(Clontech). For coimmunoprecipitation experiments of yeast expressed
proteins, we used EGY48C strains that were transformed with vectors
expressing myc-tagged Xlrbpa under the control of the Gal promoter.
HA-tagged wild type Xlrbpa was expresssed from vector pCM252
under the Tet promoter [12,13].
The third dsRBD of Xlrbpa (Xl3) was cloned into pB42-AD and
expressed as a fusion protein with the Gal4 activation domain and an
HA tag under the control of the Gal promoter. Monoclonal mouse
IgG1/k antibody 16B12, which recognizes the HA-tag, was purchased
from BABCO (Berkeley, USA). For Western blots a 1:1000 dilution
was used. 5 ll of this antibody was used for a single coimmunopre-
cipitation experiment. 9E10 is a mouse monoclonal antibody that
recognizes the myc-tag [14].
2.2. Cloning of deletion constructs
PACT was ampliﬁed from a human cDNA library using the 50
primer CGCTGATCAGTCCCTTCTCGCCATGTC and the 30 pri-
mer TTTAAGTGGATCCAGATTTACTTTCTTTC, was tagged with
a single myc at the N-terminus and subcloned into vector pLexA. The
third dsRBD of PACT (pt3), the construct consisting of the ﬁrst and
second dsRBDs of PACT (pt1:2) and deletion constructs of the third
dsRBD of Xlrbpa (xl3) were ampliﬁed by PCR using appropriate 50
primers that contained EcoRI sites and 30 primers that contained XhoI
sites. The PCR products were cloned into the same sites of vectors
pLexA or pB42AD from Clontech and sequenced prior to testing for
two-hybrid interactions.2.3. Yeast protein extracts and coimmunoprecipitation experiments
A 2 ml preculture of yeast cells was grown overnight in synthetic
medium lacking the amino acids tryptophan and leucine and con-
taining 10% galactose and 1% raﬃnose as a carbone source (SC–
Trp-Leu 10% Gal 1% Raﬀ) at 30 C. The following day, a 10 ml
culture was inoculated and grown for 5 h. For cells expressing HA-
tagged Xlrbpa from the pCM252 vector, 1 lg/ml doxycycline was
added [12,13]. The cells were pelleted and washed three times with
water. The following steps were performed on ice. The cell pellet
was resuspended in 4–5 times its volume of cold RIPA buﬀer (150
mM NaCl, 1% NP40, 0.5% DOC, 0.1% SDS, and 50 mM Tris–HCl,
pH 8.0). An equal volume of acid washed glass beads was added
and the mixture was vortexed at high speed for 30 min at 4 C.
The mixture was centrifuged at 14 000 rpm for 10 min and the
protein extract in the supernatant was transferred to a new Ep-
pendorf tube and used for coimmunoprecipitation. Typically for one
experiment, 25 ll protein G-coupled Sepharose beads and 5 ll
16B12 (anti-HA) antibody were used. The antibody was coupled to
beads in RIPA buﬀer overnight at 4 C. Next day, the beads were
washed twice with 500 ll RIPA, resuspended in 200 ll RIPA and
200 ll yeast extract (in RIPA) was added. The mixture was turned
on a wheel for 90 min at 4 C. For coimmunoprecipitations with
RNAses, 500 units of RNAseT1 and 50 lg of RNAseA were added
and the mixture was left at room temperature for 10 min before
turning at 4 C. The beads were washed four times with cold RIPA
buﬀer. To extract the proteins from the beads, 40 ll SDS loading
buﬀer was added and incubated in boiling water for 5 min. The
beads were centrifuged 5 min at full speed in an Eppendorf
centrifuge and the supernatant was directly loaded onto two small
Laemmli 10% SDS protein gels. The gels were blotted onto
nitrocellulose membranes. One membrane was developed with the
anti-HA 16B12 antibody and the other with the anti-myc 9E10
antibody.2.4. Oocyte expression and coimmunoprecipitations
For expression of Xlrbpa and constructs containing diﬀerent
dsRBD deletions, the corresponding fragments were ampliﬁed from
an Xlrbpa cDNA using primers that allowed an in-frame cloning
downstream of either a single myc-tag in pBluescript KS (Strata-
gene, LaJolla, CA) or a 6xHis tag in pRSET [3] (Amersham
Pharmacia, Uppsala, Sweden). The single third dsRBD of Xlrbpa
(Xl3) was cloned downstream of a single HA tag in pBluescript. For
RNA stability, the 30 UTR of the NO38 cDNA was added at the 30
end of all constructs [15].
For RNA synthesis, plasmids were linearized immediately down-
stream of the NO38 poly(A) tail and capped in vitro transcriptswere synthesized using bacteriophage T7 or T3 RNA polymerases as
described [16]. 50 ng of capped RNA was injected per oocyte prior
to overnight culture in OR-2 to allow protein synthesis to occur.
For double injections oocytes were cultured for 12 h after the ﬁrst
injection, followed by a second round of injection with an RNA
encoding the second construct. After the second injection, oocytes
were cultured for an additional 12 h to allow protein expression to
occur.
Expression of proteins was monitored by Western blotting of ho-
mogenized oocytes. For immunoprecipitations, antibodies were cou-
pled to protein A or protein-G Sepharose in NET-2 [17]. Oocytes were
also homogenized in NET-2 cleared of insoluble proteins by centrifu-
gation and 3 oocyte equivalents were added per immunoprecipitation.
Washed precipitates and aliquots of the crude oocyte lysates were
loaded on SDS gels. After electrophoresis, gels were blotted and pro-
teins detected using the appropriate antibodies directed against the
epitope tags.3. Results
3.1. The third dsRBD of Xlrbpa is suﬃcient for multimerization
of Xlrbpa
From a two-hybrid screen with Xlrbpa as a bait, Xlrbpa
itself was recovered as a strong interacting partner suggesting
multimerization of the protein. The smallest Xlrbpa prey
cDNAs consisted of the C-terminal end starting slightly up-
stream of the third type-B dsRBD (xl3). To ﬁnd the minimal
region of interaction, constructs with deletions from both the
N-terminal and C-terminal ends were generated by PCR,
cloned into the pB42AD prey vector, and tested for interac-
tion with Xlrbpa expressed from the bait plasmid. The
strength of the interaction was measured by quantitative b-
galactosidase liquid assays using ONPG as substrate. Fig. 1
shows the diﬀerent deletion constructs and the strength of
their interaction with Xlrbpa. The results of these experiments
identify the entire third, type-B dsRBD of Xlrbpa (xl3) as a
protein–protein interaction domain (Fig. 1). A construct with
a single amino acid deletion from the N-terminus of xl3 lost
most of its interaction ability (construct number 3, Fig. 1(a)
and (b)). A second construct with a two-amino acid deletion
from the same terminus failed to interact (construct number
2, Fig. 1(a) and (b)). The last ﬁve C-terminal residues of
Xlrbpa do not belong to the consensus of xl3 and were thus
dispensable for interaction (construct 10, Fig. 1(a) and (b)).
However, deletion of one additional residue (six residues from
C-terminus of Xlrbpa, one residue from C-terminus of the xl3
consensus) led to loss of the interaction (construct number 9,
Fig. 1(a) and (b)). Expression of the HA-tagged prey con-
structs was monitored by Western blot analysis (Fig. 1(c)).
We observed that constructs with amino acid deletions from
the C-terminal end (constructs 5, 6, 7, 8, 9 and 10) were either
weaker expressed or less stable than constructs with deletions
from the N-terminal end (constructs 2, 3 and 4) (Fig. 1(c)).
Taken together, our two-hybrid results indicate that the third
domain of Xlrbpa is suﬃcient for the self-interaction of
Xlrbpa (Fig. 1).
The constructs described so far were always cloned in the
prey plasmid and tested for an interaction with full-length
Xlrbpa in the bait plasmid. To test if xl3 can interact with it-
self, it was cloned in the bait plasmid and tested with the same
domain in the prey plasmid (Fig. 1). Xl3 proved to be suﬃcient
for a strong interaction with itself in the two-hybrid assay
(Fig. 1(b), sample 4*).
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multimerization
Having shown that xl3 can self-interact in a two-hybrid as-
say, we wanted to support this ﬁnding by biochemical analysis.
We also wanted to test whether xl3 was the only dsRBD within
Xlrbpa capable of mediating homomultimerization. Therefore,
S. cerevisiae was cotransformed with vectors expressing either
myc-tagged Xlrbpa (myc-1:2:3) or a myc tagged deletion
construct lacking the third dsRBD (myc-1:2) together with a
plasmid expressing HA-tagged xl3 as a fusion with the Gal 4
activation domain (HA-xl3). Coimmunoprecipitation (coIP)
experiments were performed from cell lysates using anti-HA
antibody coupled to protein-G Sepharose (Fig. 2(a)). In these
experiments, myc-tagged Xlrbpa (myc-1:2:3) could be eﬃ-
ciently coimmunoprecipitated with HA-xl3 (Fig. 2(a). How-
ever, a construct lacking the third dsRBD (myc-1:2) failed to
coimmunoprecipitate with HA-xl3, indicating that xl3 fails to
associate with either the ﬁrst (xl1) or with the second (xl2)
dsRBD of Xlrbpa (Fig. 2(a)). To test if xl1 and xl2 are capable
to self-interact or to interact with each other, we made coim-
munoprecipitation experiments from two yeast strains coex-
pressing HA-tagged Xlrbpa (HA-1:2:3) together with either
myc-tagged Xlrbpa (myc-1:2:3) or with a myc-tagged deletion
of Xlrbpa lacking the third dsRBD (myc-1:2) (Fig. 2(b)). As
expected, full length Xlrbpa constructs could coprecipitate
each other, while no interaction was observed between myc-1:2
and HA-1:2:3. Taken together, these results indicate that the
ﬁrst two domains of Xlrbpa xl1 and xl2 are incapable toFig. 1. The entire third dsRBD of Xlrbpa is required for protein–protein int
were cloned into the prey vector and tested for interaction with Xlrbpa th
performed to measure the strength of interaction. (a) Alignment of the diﬀe
constructs are numbered from 1 to 10. Number 1 represents the shortest inter
the minimal deletion-construct still able to interact with Xlrbpa. It exactly spa
is indicated by (+) and ()). (b) Graph of b-galactosidase units obtained by t
construct 4 is expressed both in the bait and prey vectors. (c) Western blot c
Constructs are HA-tagged, therefore the blot was developed with anti-HA an
from a strain without a bait vector were loaded. The expected size of the G
higher molecular weight (30 kDa) can be observed. The presence of th
conglomerates.multimerize, leaving xl3 as the sole domain that is necessary
and suﬃcient for the oligomerization of Xlrbpa.3.3. Multimerization of xl3 is independent of RNA binding
In vivo Xlrbpa associates with hnRNPs and ribosomes and in
vitro it is a strong dsRNA binder [1,3,18]. To investigate if
RNA-binding has an eﬀect on the oligomerization via xl3, we
performed coIP experiments from yeast extracts expressing
HA-xl3 and construct myc-1:2:3 which contains the previously
reported histidine to lysine (H141K) point mutation at position
141 in the second dsRBD that weakens theRNA-binding ability
of the whole protein [3,8]. Myc-1:2:3 interacts as strongly as
wild type Xlrbpa with xl3, suggesting that the interaction is not
aﬀected by RNA binding (Fig. 2(a)). Moreover, addition of
RNAseT1 and RNAseA showed no eﬀect on the coimmuno-
precipitation of HA-xl3 with myc-tagged wild type Xlrbpa
(myc-1:2:3) (Fig. 2(a)). These ﬁndings together with the previ-
ously reported inability of xl3 to bind dsRNA suggest that the
interaction via xl3 was not dependent on RNA-binding [3].3.4. Multimerization of Xlrbpa also occurs in Xenopus cells
To determine whether the observed interaction of xl3 with
itself would also occur in Xenopus, we expressed either myc-
tagged full length Xlrbpa (123-myc) or a deletion construct
lacking the third dsRBD (12-myc) together with the HA-tag-
ged third dsRBD of this protein (3-HA) in Xenopus oocytes.
Oocyte extracts were tested by immunoprecipitation for aneraction. The third domain of Xlrbpa (xl3) and xl3-deletion constructs
at was cloned in the bait vector. ONPG b-galactosidase assays were
rent constructs of (xl3) tested by two-hybrid assays. The xl3 deletion
acting clone recovered from the two-hybrid screen, while number 10 is
ns the minimal dsRBD consensus sequence. The strength of interaction
he constructs shown in (a). 4* indicates the b-galactosidase units when
onﬁrming the expression of constructs used in the two-hybrid assays.
tibody. Numbers refer to the constructs in (a). In ‘‘–’’ protein extracts
al4 AD-HA fusions is indicated by an arrow. In some lanes bands of
ese bands varies amongst diﬀerent gels and may represent protein
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was capable to coprecipitate full length myc-tagged Xlrbpa
(123-myc), while no interaction was observed with 12-myc, a
construct lacking the third dsRBD (Fig. 3(a)). To conﬁrm that
the ﬁrst and second dsRBDs of Xlrbpa were incapable to in-Fig. 2. Coimmunoprecipitation experiments of myc- and HA-tagged
Xlrbpa constructs. myc- and HA-tagged Xlrbpa derivatives were ex-
pressed in yeast under the control of Gal4 or tetracyclin inducible
promoters. Protein-A sepharose coupled with anti-HA antibody was
used for immunoprecipitation. Myc-1:2:3 designates myc-tagged wild
type Xlrbpa, myc-1:2:3 carries an H141K mutation that decreases
RNA-binding and construct myc-1:2 has the third dsRBD deleted.
AD-HA-xl3 expresses the third domain of Xlrbpa as a Gal4 AD+HA-
fusion, while HA-1:2:3 expresses HA-tagged full length Xlrbpa
(without Gal4 AD). (a) xl3 is suﬃcient for protein–protein interaction.
‘‘+’’ signs indicate the constructs expressed. ‘‘IP’’ indicates precipitated
proteins, while in ‘‘Extracts’’ an aliquot of the total cell lysate was
loaded. A strong interaction of xl3 (AD-HA-xl3) with Xlrbpa (myc-
1:2:3) can be detected, while construct myc-1:2 completely fails to in-
teract with AD-HA-xl3. Construct myc-1:2:3 interacts as eﬃciently as
wild type Xlrbpa with AD-HA-xl3, suggesting that RNA-binding has
no eﬀect on interaction. Addition of RNAseT1 and RNAseA (indi-
cated by +) had no eﬀect on the coIP of AD-HA-xl3 with myc-1:2:3.
(b) xl3 is essential for protein–protein interaction. coIPs of cell extracts
expressing the indicated constructs demonstrate that only constructs
containing xl3 can interact, while others fail to do so. IP: immuno-
precipitation, Ext.: protein extracts.teract with each other in oocytes, his-tagged full length Xlrbpa
(123-his) was coexpressed with either myc-tagged full length
Xlrbpa (123-myc) or a deletion construct lacking the third
dsRBD (12-myc). As observed in yeast cells, his-tagged Xlrbpa
was only able to coprecipitate full length myc-tagged Xlrbpa
but failed to show an interaction with the deletion construct
12-myc, lacking the third dsRBD (Fig. 3(b)). Taken together,
these results clearly demonstrate that only the third dsRBD
of Xlrbpa is both necessary and suﬃcient for multimeriza-
tion of Xlrbpa. At the same time, these experiments indicate
that endogenous Xlrbpa might exist as a dimer/multimer in
vivo.
3.5. The multimerization behavior of Xlrbpa is conserved in the
human homologue PACT
PACT, the human homologue of Xlrbpa, is a cellular acti-
vator of the dsRNA-activated protein kinase PKR which is a
key mediator of the antiviral eﬀects of interferons and has
functions in the regulation of cell proliferation, apoptosis and
signal transduction [19]. It was also shown that the ﬁrst two
dsRBDs of this protein are responsible for a direct protein
interaction with PKR, whereas the third domain (pt3) is the
PKR-activating domain [20,21]. Xl3 and pt3 are highly ho-
mologous to each other. Therefore, it appeared especially in-
teresting whether pt3 retained the ability to homomultimerize.
We tested this possibility by two-hybrid assays and, as ex-
pected, pt3 like xl3 turned out to be a strong protein–protein
interaction domain. In this assay, pt3 interacts eﬃciently with
wild type PACT, while a construct that consists of the ﬁrst and
second domains of PACT (pt1:2) fails to do so (Fig. 4). We
could even show that xl3 strongly interacts with pt3 (Fig. 4).
These results suggest that both in PACT and Xlrbpa, the third
domains are essential for homomultimerization.4. Discussion
In this work, we provide evidence for the oligomerization of
a highly conserved RNA-binding protein. We could show that
the homologous proteins Xlrbpa and PACT have a multi-
merization domain that consists of their third, type-B double
stranded RNA-binding domain (dsRBD).
Type-B dsRBDs fail to bind RNA as isolated domains.
However, multimerization of the type-B dsRBD xl3 could
explain how a domain that is unable to bind RNA by itself can
contribute to the overall RNA binding ability of a protein
containing additional type-A dsRBDs. Tandem arrangement
of dsRBDs enhances their RNA-binding capabilities dramat-
ically [3,4]. The ﬁrst type-A domain of Xlrbpa, for instance,
shows no detectable interaction with RNA in vitro. However,
constructs consisting of either two ﬁrst domains or a ﬁrst and a
second domain (Type-A) become potent dsRNA binders [3].
Addition of xl3 to the ﬁrst or second domains also increases
their RNA-binding ability. It appears plausible that in the
context of wild type Xlrbpa xl3 can bring two pairs of type-A
dsRBDs into close proximity, thus enhancing the RNA bind-
ing ability of the resulting complex.
Most interestingly, our observations could provide an ex-
planation for how PACT mediates PKR activation. PKR is a
ubiquitously expressed serine/threonine kinase that is induced
by interferon and activated by dsRNA. When activated by
Fig. 4. The third dsRBD of PACT is a protein–protein interaction domain. (a) Graph showing the b-galactosidase unit score of two-hybrid in-
teractions. Interaction scores of (1) the third domain of Xlrbpa (xl3) expressed as bait with xl3 expressed as prey, (2) xl3 as bait with the third domain
of PACT (pt3) as prey, (3) Full length PACT as bait with pt3 as prey, and (4) PACT as bait with a construct that contains the ﬁrst and second domain
of PACT (pt1:2) as prey. (b) TwoWestern blots were made to conﬁrm expression of the bait and prey constructs; numbers above the blots refer to the
strains in (a). The ﬁrst blot was developed with anti-HA antibody that recognizes the constructs expressed in the prey vector, the second was de-
veloped with antibody 9E10 that recognizes the myc-tag of PACT. Wild type PACT interacts with pt3 but not with pt1:2, indicating that pt3 is the
only domain that is necessary and suﬃcient for the multimerization of PACT.
Fig. 3.Multimerization inXenopus oocytes. To determine whether the third dsRBD of Xlrbpa is able to promote multimerization of Xlrbpa inXenopus
oocytes, epitope-tagged full length Xlrbpa and various deletion constructs were coexpressed in oocytes and cell lysates were used for immunopre-
cipitation experiments. (a) Full length Xlrbpa (123-myc) can be precipipitated by a single HA-tagged third dsRBD of Xlrbpa (3-HA). A construct
lacking the third dsRBD (12-myc), in contrast, cannot be precipitated by 3-HA. HA-tagged proteins were precipitated with beads to which anti-HA
antibody was coupled. IP shows the coprecipitated proteins detected with the anti-myc antibody. a-myc demonstrates expression of myc-tagged
proteins by Western blotting, while the a-HA Western blot proves expression of 3-HA. (b) Only the third dsRBD of Xlrbpa can promote multi-
merization. Full length myc tagged Xlrbpa (123-myc) can be coprecipitated by full length his-tagged Xlrbpa (123-his). While a construct lacking the
third dsRBD (12-myc) fails to interact with 123-his. (IP) Proteins were precipitated with anti-his antibody and coprecipitated myc-tagged proteins were
detected by an anti-myc antibody. (a-myc) and (a-his) demonstrate expression of the corresponding epitope-tagged proteins by Western blotting.
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the translation initiation factor subunit eIF2a [18]. The regu-
latory N-terminal region of PKR consists of two dsRNA-
binding domains (dsRBDs) in tandem arrangement, whereas
its kinase catalytic domain lies at the C-terminal end. Upon
binding RNA, PKR undergoes dimerization and transauto-
phosphorylation [22–28]. It was shown that the ﬁrst two do-
mains of PACT are responsible for a direct protein interactionwith PKR, whereas the third domain (pt3) is the PKR-acti-
vating domain [20,21]. Our observation could provide a model
for PKR activation by PACT. PACT might facilitate the di-
merization of PKR by binding PKR via its ﬁrst and second
dsRBDs like that reported previously [20,21] while dimerizing
via its third domain. This would help bringing two PKR
molecules into close proximity and thereby facilitating their
dimerization. Most interestingly, it was recently shown that the
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while the third dsRBD of its human paralogue TRBP failed to
do so [29]. PACT and TRBP are paralogous proteins showing
an almost identical molecular architecture. However, minor
diﬀerences can be observed both within dsRBDs and in the
spacer regions between them. In light of our ﬁndings, it thus
appears likely that the diﬀerent eﬀects these domains exert
on PKR activity are mediated by diﬀerent multimerization
abilities.
Finally, protein–protein interaction mediated by type B-
dsRBDs might also play a role in particle formation of the
Drosophila Staufen protein. It has been shown that Staufen
forms larger complexes that are required to transport maternal
RNAs in the early embryo. Type B dsRBDs in this protein
might therefore also be required for the observed complex
formation [30,31].
When the double-stranded RNA-binding domain was ﬁrst
discovered, it was generally believed that it exclusively func-
tions in binding to dsRNA molecules, while other parts of the
proteins would be responsible for other activities. However, it
is becoming clear that some dsRBDs have additional or more
specialized functions. The Drosophila Staufen protein, for in-
stance, has ﬁve dsRBDs, only dsRBD 1, 3, and 4 can bind
dsRNA in vitro whereas dsRBD 2 is required for the micro-
tubule-dependent localization of oskar mRNA and dsRBD5
for the derepression of oskar mRNA translation [32]. An ex-
tensive search for the nuclear localization signal (NLS) of the
RNA-editing enzyme ADAR1 identiﬁed a dsRBD as the NLS
[33]. Brownawell and Macara, in turn, identiﬁed a novel hu-
man karyopherin, exportin-5, that binds dsRBDs of several
proteins in a RanGTP dependent manner, indicating that
dsRBDs can also function as nuclear export signals [34]. Also,
dsRBDs were reported to be involved in the dimerization of
PKR and ADARs [35–40]. In these studies, however, both
RNA-binding and protein dimerization were mediated by the
same domains, while in this work we demonstrate oligomeri-
zation activity of a type B dsRBD that is incapable to bind
RNA by itself. Finally, it should be noted that while our
preliminary crosslinking experiments suggest that Xlrbpa
predominantly forms dimers in solution, there is also some
evidence for the formation of larger complexes. Thus, further
work will be required to address the question whether dsRBD3
in Xlrbpa and PACT leads to dimer or multimer formation.
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